INTRODUCTION
============

Esthesioneuroblastoma (olfactory neuroblastoma) is a rare sinonasal tumor originating from the olfactory neuroepithelium. Ectopic adrenocorticotropic hormone (ACTH) syndrome is defined as an abnormal elevation of plasma ACTH secreted from a source other than a pituitary or an adrenal gland.[@B1] New technology that uses radiolabeled somatostatin analogs, such as ^68^Ga-DOTA-conjugated positron emission tomography (PET), is useful in detecting an unidentified ectopic ACTH-producing neuroendocrine tumor.[@B2] Here, we report a case of esthesioneuroblastoma in which ^68^Ga-DOTA-conjugated PET was extremely useful.

CASE REPORT
===========

History and examination
-----------------------

A 46-year-old man without significant medical history presented with hyposmia and Cushingoid feature. On laboratory test, hypokalemia (2.6 mmol/L) was identified, and serum cortisol and plasma ACTH levels were 70.1 mcg/dL and 291.4 pg/mL, respectively. A profound increase in 24-h urine cortisol (7665 mcg/day) was also confirmed. Renin and aldosterone were within the normal range and ratio, which excluded primary hyperaldosteronism. In both low-dose and high-dose dexamethasone suppression test (DMST), cortisol was not sufficiently suppressed, which is suggestive of ectopic Cushing\'s disease, and the result of inferior petrosal sinus sampling (IPSS) was consistent with Cushing\'s disease. Sellar MRI (Achieva; Philips, Best, Netherlands) showed no pituitary enlargement or tumor and, instead, revealed a bulky mass in nasal cavity ([Fig. 1A and B](#F1){ref-type="fig"}). Due to diagnostic uncertainty on the source of ACTH secretion, we conducted nuclear imaging with a somatostatin analog tracer. The ^68^Gallium-DOTA-TOC PET scan showed strong uptake in the nasal cavity ([Fig. 1C](#F1){ref-type="fig"}). Preoperative clinical characteristics are summarized in [Table 1](#T1){ref-type="table"}. Informed consent was obtained from the patient for this report.

Operation
---------

Under the impression of an esthesioneuroblastoma causing ectopic Cushing\'s syndrome, the tumor was surgically resected. First, the intranasal portion of the tumor was removed by an endoscopic endonasal approach ([Supplementary Video 1](#S1){ref-type="supplementary-material"} only online). The tumor was very soft and hypervascular. We then performed transcranial tumor removal via a bifrontal craniotomy and an extradural approach. The tumor was radically removed together with surrounding dural layer and the anterior skull base. The galeal flap was harvested and used to cover the skull defect. From the nasal cavity, the skull defect was covered by a nasoseptal flap. Lumbar puncture was maintained until 13 days after surgery. After the surgery, the patient was closely monitored in the intensive care unit with regular measurement of serum ACTH, cortisol, and 24-h urinary free cortisol levels.

Histopathological findings
--------------------------

The histopathological diagnosis was that of an esthesioneuroblastoma with Hyams grade I ([Fig. 2A](#F2){ref-type="fig"}). Immunohistochemical staining for ACTH was positive ([Fig. 2B](#F2){ref-type="fig"}). The stains for neuron-specific enolase, synaptophysin, and chromogranin A, which are suggestive of neuroendocrine features, were positive ([Fig. 2C and D](#F2){ref-type="fig"}). Anti T-Pit stain, a reliable corticotroph marker, was negative and disfavored an ectopic ACTH-secreting pituitary adenoma ([Fig. 2E](#F2){ref-type="fig"}). Taken together, the histopathological findings were consistent with ACTH-secreting esthesioneuroblastoma.

Postoperative course
--------------------

The serum levels of both cortisol and ACTH rapidly dropped to 7.3 mcg/dL and 26.94 pg/mL at 12 hours after surgery and to 17.9 mcg/dL and less than 0.1 pg/mL on postoperative day 3. No remnant tumor was identified in 24-h postoperative brain MRI. After 1 month, the patient underwent adjuvant radiotherapy (total 55 Gy in 25 fractions). 12-month postoperative MRIs showed no recurrence ([Fig. 1D](#F1){ref-type="fig"}). DMST results and 24-h urine free cortisol levels were all normal at 3 months after surgery. Serum cortisol and plasma ACTH levels were 8.4 mcg/dL and 40.00 pg/mL, respectively, at 12 months after surgery. To date, the patient is uneventful.

DISCUSSION
==========

Esthesioneuroblastoma is a rare sinonasal tumor, that can extend to the paranasal sinuses, orbital cavity, and anterior cranial fossa.[@B3] Ectopic ACTH syndrome comprises 5--20% of Cushing\'s syndrome.[@B1][@B4] Esthesioneuroblastoma as a hormone-secreting tissue was first identified in 1967 as a syndrome of inappropriate antidiuretic hormone presentation,[@B5] and ACTH-secreting esthesioneuroblastoma was first described in 1987.[@B6]

Endocrinological workup to diagnose Cushing\'s disease includes low- and high-dose DMST, IPSS, and corticotropin releasing hormone stimulation test. When IPPSS is suggestive of pituitary ACTH secretion and MRI fails to localize a tumor in a sellar region, a dilemma arises as to whether to seek an explorative operation or not. In our case, ^68^Ga-DOTA-conjugated PET greatly helped in localizing the source of ACTH secretion in the nasal cavity and not performing unnecessary pituitary surgery. In fact, if an ectopic ACTH source is located upstream of the pituitary gland, as with, for example, an ethmoid sinus tumor, petrosal venous ACTH levels may be increased, and thus IPSS can be false positive.[@B7][@B8][@B9]

Because somatostatin receptor expression is a distinctive characteristic of neuroendocrine tumors, ^18^F-FDG PET or octreotide scintigraphy has been utilized in detecting esthesioneuroblastoma.[@B10] However, ^68^Ga-DOTA-congugated octreotide PET scan shows greater sensitivity and specificity than conventional ^18^F-FDG PET or octreotide scan.[@B11][@B12] In our case, where the results of diagnostic tests were discordant, ^68^Ga-DOTA-conjugated PET clearly demonstrated that the source of ACTH secretion was not the pituitary gland, but a tumor in the nasal cavity. This is the first report to utilize ^68^Ga-DOTA-conjugated PET to diagnosis undetected ACTH-secreting esthesioneuroblastoma.

The endoscopic endonasal approach provides great accessibility and visibility without extensive destruction of the craniofacial vault.[@B13] However, in this case, because the tumor had invaded multiple paranasal sinuses and the anterior skull base, as well as part of the frontal lobe (Kadish stage C), we accessed the tumor with combined endonasal and transcranial approaches. A high likelihood of local recurrence in the Kadish stage C tumor necessitated adjuvant radiotherapy after the surgery. Some have advocated the usefulness of chemotherapy, especially in the case of cervical metastasis or high histological grade (Hyams grade III or IV).[@B14] Because the histological grade of the tumor in this case was Hyams grade I and radical tumor removal was achieved, the patient did not undergo chemotherapy.

Without question, careful surveillance is mandatory in advanced esthesioneuroblastoma. Not only regular MRI checkup, but also ^68^Ga-DOTA-conjugated PET is useful for surveillance.[@B2] Furthermore, measuring serum cortisol and plasma ACTH directly provides helpful information. Kanno, et al.[@B7] has proposed that measurement of tumor-associated hormones is important for surveillance. Despite the potential for some unforeseen difficulties, we emphasize that using ^68^Ga-DOTA-conjugated PET and monitoring ACTH and cortisol levels comprise a reliable and convenient way through which to check for recurrence in ectopic ACTH-secreting esthesioneuroblastoma.
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SUPPLEMENTARY DATA
==================

###### Supplementary Video 1

Video 1. Removal of intranasal part of the tumor under endoscopic endonasal approach. Intranasal part of the tumor was approached under endoscopic visualization. After identification of the tumor, en bloc resection was attempted rather than piecemeal resection. As the tumor showed high vascularity, meticulous coagulation and cutting was repeated along the attachment to the nasal roof antero-posteriorly. Finally, the tumor mass was separated from the nasal roof and the entire intranasal part of the tumor was removed in one piece.

![Preoperative magnetic resonance imaging (MRI) and ^68^Ga-DOTA-congugated octreotide positron emission tomography (PET)/computed tomography (CT) scan. Axial and sagittal views of T1-weighted post-contrast MRI show a heterogeneously enhanced mass in the nasal cavity, sphenoid sinus, and frontal base (A and B). ^68^Ga-DOTA-congugated octreotide PET/CT scan reveals high somatostatin uptake in the tumor, which is suggestive of a neuroendocrine tumor (C). Twelve-month postoperative MRI shows no evidence of a remnant or recurrent tumor (D).](ymj-61-257-g001){#F1}

![High-power view of H&E staining shows small- to medium-sized neoplastic cells with lobulation. Necrosis and mitosis are not seen. Immunohistochemistry (IHC) staining for various cell markers revealed positive staining for adrenocorticotropic hormone (ACTH), neuron-specific enolase (NSE), and chromogranin A and negative staining for T-Pit. (A) H&E ×200, (B) ACTH-IHC ×200, (C) NSE-IHC ×200, (D) Chromogranin A-IHC ×200, and (E) T-Pit-IHC ×200.](ymj-61-257-g002){#F2}

###### Preoperative endocrinological and radiological evaluation

![](ymj-61-257-i001)

  Study                                                                        Results                                           
  ---------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------
  Basal hormone test                                                           Serum cortisol                                    70.1 mcg/dL (reference: 6--23 mcg/dL)
  Plasma ACTH                                                                  291.4 pg/mL (reference: 7.2--63.3 pg/mL)          
  24 hr-urine cortisol                                                         7665 mcg/day (reference: 58.00--403.00 mcg/day)   
  Low-dose DMST                                                                Not suppressed                                    
  Serum cortisol 39.9 mcg/dL, Plasma ACTH 218.90 pg/mL                                                                           
  High-dose DMST                                                               Not suppressed                                    
  Serum cortisol 34.8 mcg/dL, Plasma ACTH 159.10 pg/mL                                                                           
  IPSS                                                                         Left inferior petrosal sinus dominant             
  Basal inferior petrosal sinus/peripheral 2.4 (Reference: \>2.0)                                                                
  Sellar dynamic MRI                                                           No evidence of pituitary adenoma                  
  Tumor in the sinonasal cavity with intracranial and intraorbital extension                                                     
  ^68^Gallium-DOTA-TOC PET                                                     Suggesting neuroendocrine tumor in nasal cavity   
  Normal hot uptake of pituitary grand                                                                                           
  Whole body bone scan                                                         No distant metastasis                             

ACTH, adrenocorticotropic hormone; DMST, dexamethasone suppression test; IPSS, inferior petrosal sinus sampling; MRI, magnetic resonance imaging; PET, positron emission tomography.
